ATE328582T1 - Antikörper und polyalkylenglycol gebundenes liposom - Google Patents

Antikörper und polyalkylenglycol gebundenes liposom

Info

Publication number
ATE328582T1
ATE328582T1 AT00917390T AT00917390T ATE328582T1 AT E328582 T1 ATE328582 T1 AT E328582T1 AT 00917390 T AT00917390 T AT 00917390T AT 00917390 T AT00917390 T AT 00917390T AT E328582 T1 ATE328582 T1 AT E328582T1
Authority
AT
Austria
Prior art keywords
liposome
polyalkylene glycol
antibodies
bonded liposome
glycol bonded
Prior art date
Application number
AT00917390T
Other languages
English (en)
Inventor
Toshiaki Tagawa
Saiko Hosokawa
Original Assignee
Mitsubishi Chem Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chem Corp filed Critical Mitsubishi Chem Corp
Application granted granted Critical
Publication of ATE328582T1 publication Critical patent/ATE328582T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00917390T 1999-04-23 2000-04-20 Antikörper und polyalkylenglycol gebundenes liposom ATE328582T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11573899 1999-04-23
JP11573799 1999-04-23

Publications (1)

Publication Number Publication Date
ATE328582T1 true ATE328582T1 (de) 2006-06-15

Family

ID=26454194

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00917390T ATE328582T1 (de) 1999-04-23 2000-04-20 Antikörper und polyalkylenglycol gebundenes liposom

Country Status (11)

Country Link
US (1) US20080014255A1 (de)
EP (2) EP1174126B1 (de)
JP (1) JP4111368B2 (de)
KR (1) KR100699059B1 (de)
CN (2) CN1561968A (de)
AT (1) ATE328582T1 (de)
AU (1) AU766570B2 (de)
CA (1) CA2370043A1 (de)
DE (1) DE60028567T2 (de)
ES (1) ES2265340T3 (de)
WO (1) WO2000064413A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8352400B2 (en) 1991-12-23 2013-01-08 Hoffberg Steven M Adaptive pattern recognition based controller apparatus and method and human-factored interface therefore
US7904187B2 (en) 1999-02-01 2011-03-08 Hoffberg Steven M Internet appliance system and method
GB9915074D0 (en) * 1999-06-28 1999-08-25 Cortecs Plc Ligand-binding composition
AU2002259107B2 (en) * 2001-04-30 2006-10-26 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
JPWO2003009870A1 (ja) * 2001-07-25 2004-11-11 三菱ウェルファーマ株式会社 乳癌治療薬
KR100470535B1 (ko) * 2002-06-27 2005-02-22 재단법인서울대학교산학협력재단 유피에이 항체 부착 이뮤노리포좀
CA2501222A1 (en) 2002-10-04 2004-10-21 Mitsubishi Pharma Corporation Antibody recognizing antigen
US20070112176A1 (en) * 2003-04-04 2007-05-17 Daiichi Pharmaceutical Co., Ltd. Lipid membrane structure containing anti-mt-mmp monoclonal antibody
SI1639011T1 (sl) * 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
JPWO2006030602A1 (ja) * 2004-09-16 2008-05-08 田辺三菱製薬株式会社 卵巣癌の診断および／または治療薬
JP5110880B2 (ja) 2004-11-18 2012-12-26 テルモ株式会社 医薬組成物、製剤および組み合わせ製剤
JP2008536815A (ja) 2005-03-14 2008-09-11 メディミューン，エルエルシー チオエーテル架橋を含む巨大分子
US20110096174A1 (en) * 2006-02-28 2011-04-28 King Martin T Accessing resources based on capturing information from a rendered document
US9814672B2 (en) * 2007-03-09 2017-11-14 Susan T. Laing Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi
US20100080773A1 (en) * 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
US8846053B2 (en) 2008-09-26 2014-09-30 Sdg, Inc. Orally bioavailable lipid-based constructs
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
JP5593488B2 (ja) 2008-11-17 2014-09-24 独立行政法人国立がん研究センター 癌間質の構成因子に対して特異的結合能を有する物質と抗腫瘍性化合物との複合体による新規の癌ターゲティング治療
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
US8747869B2 (en) 2010-03-19 2014-06-10 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
US20150174209A1 (en) 2012-05-25 2015-06-25 Amylin Pharmaceuticals. Llc Insulin-pramlintide compositions and methods for making and using them
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
SG11201908052PA (en) 2017-03-13 2019-09-27 Sdg Inc Lipid-based nanoparticles with enhanced stability
EP3600422B1 (de) 2017-03-31 2023-10-18 The Regents of the University of California Zusammensetzungen zur verwendung in dem verfahren zum abzielen und töten von alpha-v beta-3-positiven krebsstammzellen (cscs) und in der behandlung von arzneimittelresistenten tumoren
JP7284470B2 (ja) 2019-05-29 2023-05-31 株式会社エフ・ピー・エス 生体分子の検出のための温度応答性蛍光粒子

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US6787153B1 (en) * 1991-06-28 2004-09-07 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
JP3351476B2 (ja) * 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム

Also Published As

Publication number Publication date
KR20020011977A (ko) 2002-02-09
CN1561968A (zh) 2005-01-12
DE60028567T2 (de) 2007-05-16
WO2000064413A1 (en) 2000-11-02
AU3840700A (en) 2000-11-10
AU766570B2 (en) 2003-10-16
EP1174126B1 (de) 2006-06-07
CA2370043A1 (en) 2000-11-02
DE60028567D1 (de) 2006-07-20
US20080014255A1 (en) 2008-01-17
ES2265340T3 (es) 2007-02-16
CN1355691A (zh) 2002-06-26
KR100699059B1 (ko) 2007-03-23
EP1174126A1 (de) 2002-01-23
EP1563832A1 (de) 2005-08-17
CN1198590C (zh) 2005-04-27
EP1174126A4 (de) 2002-09-04
JP4111368B2 (ja) 2008-07-02

Similar Documents

Publication Publication Date Title
DE60028567D1 (de) Antikörper und polyalkylenglycol gebundenes liposom
DE69226739D1 (de) Arzneimittel enthaltend Protein-gebundende Liposome
DK0783297T3 (da) Polyethylenglycol-modificerede ceramid-lipider og liposomer
DE69128968D1 (de) Biologisch aktive bakterizide/permeabilitätserhöhende proteinbruchstücke
FI933740A0 (fi) Peg-interferonkonjugat
DE3586948D1 (de) Polyamidsaeure-loesung und daraus hergestellter film.
TR200201921T2 (tr) İyileştirilmiş pediyatrik formülasyon ve beslenme temin etmek ve tolerans geliştirmek için yöntemler.
DE3789382D1 (de) Phosphor enthaltendes schmiermittel und funktionelle fluidzubereitungen.
IT1203515B (it) Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
FR2589359B1 (fr) Canule aortique
ATE46513T1 (de) Komplexe aus flavanolignanen mit phospholipiden, herstellung davon und verbundene arzneimitteln.
ATE223204T1 (de) Liposomenzusammensetzung
ATE82857T1 (de) Interleukin-2-zusammensetzungen.
ATE376523T1 (de) Arzneimittelträger
DK0509338T3 (da) Fremstilling og anvendelse af stabile præparater af liposomer med lille partikelstørrelse
TR23919A (tr) Atomize edici meme ve kullanimi.
TR199501039A2 (tr) Omega-hidrokarboksilik asit birimleri iceren lineer kopoliyesterleri hazirlama islemi.
ES2124328T3 (es) Liposomas que contienen diacetato de clorhexidina o digluconato de clorhexidina.
IT1188080B (it) Dispositivo invertitore di pacchetti in particolare di pacchetti di sigarette o simili
ITMI941469A0 (it) Proteine ad attivita' antitumorale
DE3671638D1 (de) Polyphenylenaether und polyamid enthaltende polymerzusammensetzung.
FR2559066B1 (fr) Canule d'aspiration des graisses
DE3868603D1 (de) Absorbensmittel fuer ungebundenes haemoglobin.
IT8622398A0 (it) Strumento di mira per la puntura dicavita' renali.
AT384361B (de) Absaugkanuele

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties